BioMarin Pharmaceutical | BMRN - Ebit



金融业
股票价格
USD
资产
USD 8.59B
现金及等价物
USD 2.22B
销售成本
USD 199.48M
流动资产
USD 4.61B
流动负债
USD 793.15M
债务
USD 1.44B
EBIT
USD 129.65M
EBITDA
USD 146.05M
员工
3.04K
EPS每股收益
USD 0.76
股本和储备
USD 6.21B
销售毛利
USD 571.21M
债务利息支出
USD 14.96M
利息收入
USD 22.56M
贷款资金
USD 1.43B
市值
USD 10.61B
净收入
USD 105.53M
营业费用
USD 636.56M
营业利润
USD 129.65M
普通股股本
USD 193.27M
PE价格收益
15.28
税前利润
USD 141.2M
销售收入
USD 766M
销售和管理费用
USD 258.28M
股票
USD 1.27B
贸易债权人
USD 793.15M
应收帐款人
USD 903.91M


Ebit 更改 日
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Amgen USD 3.83B 130M 2026-03
Bayer EUR 3.53B 2.42B 2026-03
Biogen USD 514.3M 502.8M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Gilead Sciences USD 2.68B 284M 2026-03
Incyte USD 344.17M 39.71M 2026-03
Insmed USD -200.28M 49.43M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
Moderna USD -1.39B 531M 2026-03
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
PTC Therapeutics USD 45.89M 127.51M 2026-03
Puma Biotechnology USD -2.2M 11.41M 2024-06
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Roche Holding CHF 9.56B 2.1B 2025-12
Sanofi EUR 3.74B 2.23B 2025-09
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
United Therapeutics USD 325.8M 340.4M 2026-03
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03